title: Copeptin in Heart Failure.
abstract: Heart failure (HF) is one of the most common causes of hospitalization and mortality in the modern Western world and an increasing proportion of the population will be affected by HF in the future. Although HF management has improved quality of life and prognosis, mortality remains very high despite therapeutic options. Medical management consists of a neurohormonal blockade of an overly activated neurohormonal axis. No single marker has been able to predict or monitor HF with respect to disease progression, hospitalization, or mortality. New methods for diagnosis, monitoring therapy, and prognosis are warranted. Copeptin, a precursor of pre-provasopressin, is a new biomarker in HF with promising potential. Copeptin has been found to be elevated in both acute and chronic HF and is associated with prognosis. Copeptin, in combination with other biomarkers, could be a useful marker in the monitoring of disease severity and as a predictor of prognosis and survival in HF.
authors.affiliation: Department of Cardiology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark. Electronic address: louise.balling@dadlnet.dk.
authors.forename: Louise
authors.initials: L
authors.lastname: Balling
authors.affiliation: Department of Cardiology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
authors.forename: Finn
authors.initials: F
authors.lastname: Gustafsson
mesh_terms: D015415:Biomarkers / Q000097:blood; D006020:Glycopeptides / Q000097:blood* / Q000378:metabolism*; D006333:Heart Failure / Q000097:blood* / Q000175:diagnosis* / Q000628:therapy; D006801:Humans
chemical_list: D015415:Biomarkers; D006020:Glycopeptides; C048197:copeptins
keywords: AVP; Biomarker; Copeptin; Heart failure; Hyponatremia; Neurohormonal activation; Osmoregulation; Vasopressin